GIST refractory to imatinib treatment
Onozawa, Y.; Terashima, M.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(5): 738-743
2011
ISSN/ISBN: 0385-0684 PMID: 21566433 Document Number: 650797
After the introduction of imatinib, the outcome for patients with advanced gastro-intestinal stromal tumor (GIST) was vastly improved. However, resistance to imatinib has become a new problem. The cause of resistance to imatinib is the low sensitivity of gene mutations in the KIT gene or PDGFRα, or an acquisition of additional mutations, and a low plasma level of imatinib. Sunitinib is the first drug that showed an effectiveness for treating GIST refractory to imatinib. New molecular target drugs for overcoming imatinib resistance are being developed now.
Document emailed within 1 workday
Related Documents
Sakamoto, Y.; Akimoto, H.; Kojo, M.; Kawano, H.; Chinen, Y.; Morita, K.; Sugiyama, M.; Saeki, H.; Minami, K.; Soejima, Y.; Sakaguchi, Y.; Toh, Y.; Okamura, T. 2011: A case of imatinib-resistant GIST treated by sunitinib Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(5): 827-830Feki, J.; Marrekchi, G.; Boudawara, T.; Rekik, N.; Maatouq, S.; Boudawara, Z.; Frikha, M. 2015: Subdural hematoma during therapy of gastro-intestinal stromal tumor (GIST) with Imatinib mesylate Gulf Journal of Oncology 1(17): 92-95
Suzuki, N.; Yoshino, S.; Somura, H.; Ueno, T.; Oka, M. 2009: A case of rapid growth GIST successfully treated with resection after long-term use of imatinib Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(12): 2354-2356
Gelibter, A.; Milella, M.; Ceribelli, A.; Zeuli, M.; Ferraresi, V.; Vecchione, A.; Cognetti, F. 2004: PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients Anticancer Research 24(5b): 3147-3151
Okuda, H.; Tanaka, H.; Ueno, M.; Shitani, M.; Nasuno, M.; Suzuki, C.; Nishimura, S.; Kimura, H.; Yonezawa, K.; Abe, T.; Yoshida, Y.; Kawabata, M. 2005: A case of Giant GIST of the stomach successfully treated with imatinib mesylate neoadjuvant therapy and followed postoperatively Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(12): 1941-1944
Tonooka, T.; Takiguchi, N.; Yamamoto, H.; Nabeya, Y.; Ikeda, A.; Kainuma, O.; Souda, H.; Cho, A.; Muto, Y.; Yanagibashi, H.; Takano, E.; Denda, T.; Nagata, M. 2014: A case of rectal gastrointestinal stromal tumor (GIST) locally resected after long-term chemotherapy with imatinib mesylate Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(12): 1849-1851
Shi, R.; Lin, J.; Guo, Y.; Gong, Y.P. 2014: The MEK1/2 inhibitor U0126 reverses imatinib resistance through down-regulating activation of Lyn/ERK signaling pathway in imatinib-resistant K562R leukemia cells Die Pharmazie 69(5): 346-352
Scheinfeld, N. 2006: Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate Journal of Drugs in Dermatology: Jdd 5(3): 228-231
Fattoruso, S.I.S.; Lopez, M. 2008: A step foward in the treatment of GIST La Clinica Terapeutica 159(4): 223-224
Balwierz, W.; Pawińska, K.; Skoczeń, S.; Klekawka, T.; Strojny, W.; Niezgoda, A. 2004: Perspectives in the use of imatinib in the treatment of childhood cancers Przeglad lekarski 61 Suppl. 2: 95-99
Kasatkin, V.F.; Snezhko, A.V.; Fomenko, I.A. 2012: The esophagus extirpation with the extended right hemihepatectomy as the surgical treatment of the giant GIST-tumor Khirurgiia 6: 60-61
O'Dwyer, M. 2003: Current use of imatinib in the treatment of chronic myeloid leukemia Haematologica 88(3): 241-244
Vendettuoli, M.; Pironi, D.; Pontone, S.; Panarese, A.; La Gioia, G.; Arcieri, S.; Romani, A.M.; Palazzini, G.; Filippini, A. 2012: Gastrointestinal stromal tumors treatment in the Imatinib era. the role of fair indication Minerva Chirurgica 67(2): 165-173
Garrido S, M.; Moneada M, Mónica.; Tapia N, G.; Méndez O, G.; Galindo A, Héctor.; Huete G, A.; Ibáñez A, L.; González, S.; Alvarez Z, M. 2007: Treatment of metastatic gastrointestinal stromal tumors with Imatinib: report of four cases Revista Medica de Chile 135(10): 1327-1332
Bar-Sela, G.; Lev, L.M.; Kuten, A.; Wollner, M.; Haim, N. 2006: Treatment of gastrointestinal stromal tumors with imatinib mesylate: a center-based study of 13 patients Harefuah 145(1): 2-7 80
Gelderblom, H.; Hogendoorn, P.C.; van der Graaf, W.T.; Verweij, J. 2003: Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor Nederlands Tijdschrift Voor Geneeskunde 147(42): 2051-2055
Molnár, L.; Nagy, A.; Dávid, M.; Szomor, A.ád.; Méhes, G.áb.; Kovács, G.áb.; Losonczy, H. 2004: Results of imatinib therapy in late-stage chronic myeloid leukemia after treatment with interferon-alpha Orvosi Hetilap 145(17): 901-907
Sawaki, A.; Inaba, K.; Nomura, S.; Kanie, H.; Yamada, T.; Hayashi, K.; Okawaki, M.; Yamamura, M.; Yamaguchi, Y.; Hirai, T.; Orito, E. 2014: Imatinib plasma levels during successful long-term treatment of metastatic-gastrointestinal stromal tumors Hepato-Gastroenterology 61(135): 1984-1989
Gordon, J.; Udeh, U.; Doobay, K.; Magro, C.; Wildman, H.; Davids, M.; Mersten, J.N.; Huang, W.-T.; Lyman, S.; Crow, M.K.; Spiera, R.F. 2014: Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial Clinical and Experimental Rheumatology 32(6 Suppl 86: S
Toyokawa, T.; Teraoka, H.; Kitayama, K.; Nomura, S.; Kanehara, I.; Nishino, H. 2014: A case report of two-term surgery for focal progression of a huge liver metastasis and peritoneal dissemination from gastrointestinal stromal tumor during imatinib mesylate treatment Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(3): 373-377